Hemolytic uremic syndrome in renal allografted patients treated with cyclosporin.
The classical triad of hemolytic uremic syndrome (microangiopathic hemolytic anemia, severe thrombopenia, and renal failure) developed de novo in three of our renal transplanted patients under cyclosporin A treatment. The predominant morphologic findings in the grafts consisted of glomerular and arteriolar thrombosis as well as arteriolonecrosis, all features of the syndrome. In one instance, ischemic bowel disease supervened after graft removal and was associated with persistent low grade microangiopathic process. De novo hemolytic uremic syndrome has been reported in patients treated with cyclosporin A following bone marrow or liver transplantation as well as in a few renal graft recipients. This peculiar form of cyclosporin A nephrotoxicity should not be confused with acute rejection of the renal transplant.
Giroux
L
L
Smeesters
C
C
Corman
J
J
Paquin
F
F
Allaire
G
G
St-Louis
G
G
Daloze
P
P
D000328:Adult; D003524:Cyclosporins / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
D003524:Cyclosporins